Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01057901 · ClinicalTrials.gov registry record · Phase 3
Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women in North America
A Phase 3 study, sponsored by Sprout Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 748
- Enrollment target
NCT01057901 is a Phase 3 study that was terminated before completion, run by Sprout Pharmaceuticals. The registered enrollment target is 748 participants.
The verdict
NCT01057901, a Phase 3 study, was terminated before completion, sponsored by Sprout Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 748 participants
- Enrollment target
Study Summary
The objective of this trial is to assess the safety and efficacy of 24-week course of flibanserin for the treatment of Hypoactive Sexual Desire Disorder (HSDD) in naturally postmenopausal women.
Interventions
- DRUG Placebo
- DRUG Flibanserin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 748 participants |
| Start Date | 2010-01 |
| Est. Completion | 2011-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01057901
The ClinicalTrials.gov registry entry for NCT01057901 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 748 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sprout Pharmaceuticals, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01057901 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01057901 about?
NCT01057901 is a clinical study titled "Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women in North America". The objective of this trial is to assess the safety and efficacy of 24-week course of flibanserin for the treatment of Hypoactive Sexual Desire Disorder (HSDD) in naturally postmenopausal women.
What is the current status of trial NCT01057901?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 748 participants. The study started on 2010-01. Estimated completion is 2011-01.
What interventions are being tested in trial NCT01057901?
The interventions under investigation include: Placebo (DRUG), Flibanserin (DRUG).
Who is sponsoring clinical trial NCT01057901?
This trial is sponsored by Sprout Pharmaceuticals, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.